Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWE3GB)

• Drug Name: TG-4010 Drug Info
• Synonyms: MVA-Muc1-IL-2; MVA-TG-9931 (frozen suspension); MUC1/IL-2 antigen therapy (gene transfer system, cancer), Transgene

Indication

Disease Entry	ICD 11	Status	REF
Bipolar disorder	6A60	Phase 2/3	[1]
Non-small-cell lung cancer	2C25.Y	Phase 2/3	[2]

• Cross-matching ID: TTD Drug ID: DMWE3GB

Molecule-Related Drug Atlas

Drug(s) Targeting Mucin-1 (MUC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Yttrium (90Y) clivatuzumab tetraxetan	DMOLR5W	Pancreatic cancer	2C10	Phase 3	[3]
ICO-25	DMC13BQ	Breast cancer	2C60-2C65	Phase 2	[4]
MUC1-Poly-ICLC	DML7N4B	Colorectal cancer	2B91.Z	Phase 2	[5]
AS-1402	DMMX1EJ	Breast cancer	2C60-2C65	Phase 2	[6]
Emepepimut-S	DMCLT2F	Non-small-cell lung cancer	2C25.Y	Phase 2	[7]
GO-203-2c	DMLWKZ7	Acute myeloid leukaemia	2A60	Phase 2	[8]
SAR-566658	DMT4FI5	Triple negative breast cancer	2C60-2C65	Phase 2	[9]
Pankomab-GEX	DMAZ460	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
ImMucin	DM09JOZ	Multiple myeloma	2A83	Phase 1/2	[11]
G0-203-2c	DMG48WN	Pancreatic cancer	2C10	Phase 1/2	[8]

Drug(s) Targeting Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldesleukin	DM4YMIS	Acute myelogenous leukaemia	2A41	Approved	[12]
Daclizumab	DM6OZQV	Aplastic anemia	3A70	Approved	[13]
AIR-insulin	DM8SYTE	Diabetic complication	5A2Y	Phase 3	[14]
BNZ-1	DM8JQZC	Cutaneous T-cell lymphoma	2B01	Phase 2	[15]
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[16]
Carboxyamidotriazole orotate	DMN5JCX	Glioblastoma multiforme	2A00.0	Phase 2	[17]
Leuvectin	DM5LQEI	Melanoma	2C30	Phase 2	[18]
Human interleukin-2	DM0NJWG	Renal cell carcinoma	2C90	Phase 2	[19]
L19-IL-2 fusion protein	DMI2XP1	Lymphoma	2A80-2A86	Phase 2	[20]
Thymoctonan	DM4BLJM	Immune System disease	4A01-4B41	Phase 2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-2 (IL2)	TTF89GD	IL2_HUMAN	Modulator	[1]
Mucin-1 (MUC1)	TTBHFYQ	MUC1_HUMAN	Modulator	[1]

References

• [1] A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of Immunomedics.
• [4] The role of epithelial antigens in diagnosis and staging of breast cancer. Arkh Patol. 2002 Nov-Dec;64(6):13-5.
• [5] Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2013 Mar 1;2(3):e23429.
• [6] Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73.
• [7] Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7.
• [8] Clinical pipeline report, company report or official report of Genus Oncology.
• [9] Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73.
• [10] Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol. 2013 Feb;28(2):239-44.
• [11] Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015 Apr;169(1):44-56.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [14] The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
• [15] Clinical pipeline report, company report or official report of Bioniz Therapeutics.
• [16] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [17] J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
• [18] Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
• [19] Clinical pipeline report, company report or official report of Immunservice.
• [20] National Cancer Institute Drug Dictionary (drug id 665656).
• [21] Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol. 1995 Jul;23(1):21-7.